A multicenter, patient-masked, safety extension study to evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system [more info]

A 3-month, multicenter, Investigator-Masked, Pilot Study to evaluate the eficacy and safety of Bimatoprost/Timolol fixed combination vs Latanoprost in treatment-Naive patients with Open-Angle Glaucoma at high risk of Glaucomatous progression. [more info]

An evaluation of the Ocular Surface Health in subjects using DuoTrav APS eye drops solution versus Xalacom® eye drops solution [more info]

Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using non-invasive procedures [more info]

Prospective, randomized, multicenter, open label phase II study to assess eficacy and safety of Lucentis® monotheraphy (ranibizumab 0.5mg intravitreal injections) compared with Lucentis® plus panretinal photocoagulation (PRP) and PRP (monotheraphy) in the treatment of patients with high risk proliferative diabetic retinopathy. [more info]

Prospective, randomized, open label phase II study to assess eficacy and safety of Macugen® (pegaptanib 0.3mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotheraphy) in the treatment of patient with high risk proliferative diabetic retinopathy [more info]

Correlation phenotype/genotype in diabetic retinopathy [more info]

Age Related Macular Degeneration [more info]

A three-month, multicenter, double-masked study comparing the safety and efficacy of the fixed combination Travoprost/Brinzolamide Eye Drops, suspension vs Travantan vs Azopt in patients with open-angle glaucoma or ocular hypertension. [more info]

A multicenter, masked, randomized, sham-controlled, paired-eye comparison, 12-month (plus 12-month extension) study to evaluate the safety and effects on Retinal Structure and Visual Function of Brimonidine tartrate posterior segment drug delivery system (Brimonidine Tartrate PS DDS) applicator system in patients with Geographic atrophy from Age-related Macular Degeneration [more info]

A randomized, double-masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trop-Eye in subjects with neovascular age-related [more info]

Long term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered at the therapeutic recommended doses (2.5/5/7.5 mg b.i.d.) on top of anti anginal background therapy, to patients with chronic stable angina pectoris. An international, double-blind placebo controlled study [more info]

A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.003mg Pagaptanib Sodium (Macugen®), Given as Often as Every 6 Weeks for 3 years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) involving the Center of the Macula [more info]

A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema [more info]

A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and afety of 0.5mg and 1.25mg fingolimod (FTY720) administered orally once daily versus interferon ?-1a (Avonex®) administered i.m. Once weekly in patients with relapsing-remitting multiple sclerosis [more info]

An extension of the double-blind, randomized, placebo-controlled, parrallel-group, multicenter study evaluating safety, tolerability and effet on MRI lesion parameters of FTY720 vs placebo in patients with relapsing multiple sclerosis [more info]

The effect of Ruboxistaurin on Clinically significant macular edema in patients with diabetes Mellitus, as assessed by optical coherence tomography [more info]

Areas of expertise

•  Characterisation and evaluation of the most recent methods to study the initial stages of diabetic retinopathy and age-related macular degeneration.
• Identification of phenotypes and biomarkers of retinal disease progression.
• Evaluation of new methodologies for multimodal mapping of the macula.
• Correlation between structure-function with psychophysics tests to study the early signs of retinal disease.
• Testing new methods of early diagnosis and characterisation of macular edema and retinal vascular pathology.
• Evaluation of new drugs to treat glaucoma. Development of methods to correlate clinical indicators of disease progression, particularly regarding optic nerve degeneration and the mechanisms of the actions of drugs being tested.